DRRX (DURECT Corp) Rega marang bathi mangsa ngarep

DURECT Corporation (DRRX) is developing the drug Larsucosterol for the treatment of alcoholic hepatitis, leveraging a team of dedicated biochemists and compliance experts. The historical forward P/E ratio of DURECT Corporation (DRRX) confirms the valuation trend, with the indicator currently standing at 0.00. Intellectual property protection for the molecules and strict FDA oversight minimize competition, creating conditions for a natural monopoly within the epigenetics niche.

DRRX - Kapitalisasi marang proyeksi bathi DURECT ing rentang 04.07.2022 - 27.09.2025

Ringkesan rincian data analitis durect.com (DRRX)

- rega saiki lan proyeksi nilai saham:

Kutipan saham DURECT Corp|DRRX - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Nilai pasar DURECT Corporation|DRRX - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Nilai Buku saben Saham DURECT|DRRX - Pambiji Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih durect.com|DRRX - Aset Agregat Perusahaan

- statistik kawajiban utang lan likuiditas:

Total Utang marang Modal DURECT Corporation|DRRX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas DURECT Corp|DRRX - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku DURECT Corporation|DRRX - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan DURECT|Likuiditas cepet durect.com

- statistik bathi lan rasio pasar:

DRRX - Bathi pungkasan|Proyeksi bathi mangsa ngarep DURECT Corporation|DRRX - Kapitalisasi marang bathi|Pangali Forward P/E DURECT Corp|DRRX - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan DURECT Corp|DRRX - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan DURECT|DRRX - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan durect.com|DRRX - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep DURECT Corporation

- data pendapatan lan penerimaan dodolan:

DRRX - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan DURECT Corp|DRRX - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang prakiraan pendapatan DURECT Corp.|DRRX - Wutah dodolan taun lumaku

Pambiji fundamental:durect.com

DURECT Corporation is developing innovative therapies where success depends on Larsucosterol clinical trials and partnerships with pharmaceutical behemoths. By analyzing the company's forward P/E ratio, an investor assesses current capitalization relative to projected earnings to determine the premium for future growth. Sharp fluctuations in this indicator signal a market revision of yield expectations, which is critical during any deviation from planned financial results.

Karo sapa DURECT Corporation saingan

Prakiraan rega marang bathi ARWR (Arrowhead Pharmaceuticals Inc)|MIRM (Mirum Pharmaceuticals Inc) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Dynavax Technologies Corporation DVAX|Arbutus Biopharma - Rega marang bathi mangsa ngarep|IVA: Prakiraan rega marang bathi|Kapitalisasi marang proyeksi bathi Gyre Corp GYRE|ASMB (Assembly Biosciences Inc) - Prakiraan rega marang bathi|GALT (Galectin Therapeutics, Inc.) - Rega marang bathi mangsa ngarep|GNFT (Genfit SA) - Pangali Forward P/E|Rasio prakiraan rega marang bathi aligos.com ALGS|Rega marang bathi mangsa ngarep BioVie Inc (BIVI)|GLMD (Galmed Pharmaceuticals Ltd.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E NDRA (endrainc.com)|Pangali mangsa ngarep rega marang bathi HEPA